Featured Research

from universities, journals, and other organizations

Mayo Clinic Study Finds Brief Fibromyalgia Treatment Program Reduces Some Symptoms

Date:
April 10, 2001
Source:
Mayo Clinic
Summary:
Mayo Clinic researchers have found that a brief interdisciplinary treatment program for fibromyalgia reduces some symptoms, especially in people more severely affected by this chronic disorder.

ROCHESTER, MINN. -- Mayo Clinic researchers have found that a brief interdisciplinary treatment program for fibromyalgia reduces some symptoms, especially in people more severely affected by this chronic disorder.

The results of this study should help physicians develop a beneficial and convenient treatment program for patients with fibromyalgia. The study appears in the April issue of Mayo Clinic Proceedings.

Fibromyalgia is characterized by a cluster of symptoms that include: diffuse pain, stiffness and fatigue. The 1990 American College of Rheumatology criteria for diagnosing fibromyalgia are widespread pain and tenderness at 11 of 18 specific tender points. Fibromyalgia is perceived by many people as a disabling condition. Almost 20 percent of fibromyalgia patients have applied for disability benefits, and more than seven percent have received such benefits.

Fibromyalgia is a frustrating condition without a known cause or a widely accepted treatment, and current therapeutic practices are often inadequate.

"Knowing that brief interdisciplinary treatment programs for fibromyalgia are effective is important for tertiary care centers whose patients often do not live nearby," says Lois Krahn, M.D., a Mayo Clinic psychiatrist and one of the authors of the study. "Brief, intense programs provide an approach for treating patients who stay in the area for only a few days."

This study evaluated the efficacy of the Fibromyalgia Treatment Program (FTP) at Mayo Clinic. This program contains the traditional medical, educational, self-management and occupational/physical therapy components. Unlike most interdisciplinary treatment programs that are carried out over many weeks with one meeting or more per week, this program is consolidated into one-and-one-half days. The FTP is a three-part interdisciplinary program. The first half-day involves evaluation of patients by a nurse and a physician, including medical, physical, psychological, educational and pharmacological assessments. The second half-day segment consists of a nurse-led course with an emphasis on self-management. The third half-day portion includes both physical and occupational therapy components led by physical and occupational therapists.

The study assessed 100 patients after they were referred to and evaluated in the Fibromyalgia Treatment Program from Feb. 14, 2000, to May 9, 2000.

Pain, number of bad days per week, morning and daytime fatigue, stiffness, nervousness and anxiety and overall effect of this condition on patients’ lives were all shown to improve at the one-month follow-up analysis, the study’s authors reported.

Conflicting information in the literature combined with the results from this study suggest that predicting which fibromyalgia patients will benefit from an interdisciplinary treatment program is difficult. "Simply put, all patients have the potential to benefit from these programs," the study’s authors write.

The study also showed that patients with a history of depression were more affected by fibromyalgia than those without a history of depression. Although no data exists to indicate whether these patients were depressed at the time of treatment, these findings suggest that properly identifying and treating depression is important in treating fibromyalgia.

Mayo Clinic Proceedings is a peer-reviewed and indexed general internal medicine journal, published for 75 years by Mayo Foundation, with a circulation of 130,000 nationally and internationally.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Mayo Clinic Study Finds Brief Fibromyalgia Treatment Program Reduces Some Symptoms." ScienceDaily. ScienceDaily, 10 April 2001. <www.sciencedaily.com/releases/2001/04/010410084758.htm>.
Mayo Clinic. (2001, April 10). Mayo Clinic Study Finds Brief Fibromyalgia Treatment Program Reduces Some Symptoms. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2001/04/010410084758.htm
Mayo Clinic. "Mayo Clinic Study Finds Brief Fibromyalgia Treatment Program Reduces Some Symptoms." ScienceDaily. www.sciencedaily.com/releases/2001/04/010410084758.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins